AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition.
Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen (NASDAQ:AMGN), Teva (NYSE:TEVA), and Pfizer (NYSE:PFE) onto the market. After factoring over a third of AbbVie's income in 2022, Humira's share fell to 27% in 2023.
Humira still dominated 96% of the market as of February 2024, but its share dropped to 77% in May after several pharmacy benefit managers, notably CVS Health (CVS), kicked it off important formularies.AbbVie has 72% of the adalimumab market as of November 2024; biosimilars are taking center stage, rising from 2% to 23% in a year. Humira is still the leading market participant even with the evolving rivalry.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。